Home > Journals > Medicine > Hématologie > summary
 
      Advanced search    Shopping cart    French version 
 
Latest books
Catalogue/Search
Collections
All journals
Medicine
Hématologie
- Current issue
- Archives
- Subscribe
- Order an issue
- More information
Biology and research
Public health
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Subscribe
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
Newsletters
How can I publish?
Journals
Books
Help for advertisers
Foreign rights
Book sales agents



 

Texte intégral de l'article
 
Printable version

TREM-like transcript-1: at the frontier between haemostasis and inflammation


Hématologie. Volume 17, Number 6, 435-9, Novembre-Décembre 2011, Mini-revue

Résumé   Texte intégral  

Author(s) : Marc Derive, Sébastien Gibot

Summary : TLT-1 (TREM-Like Transcript-1) is a novel platelet membrane receptor which has been recently characterized and identified to play an important role in platelet biology. TLT-1 belongs to the Triggering Receptors Expressed on Myeloid cells (TREMs) family which includes several immunoreceptors expressed by innate immune cells. TLT-1 is exclusively expressed on megakaryocytes and platelets, sequestered in α-granules and rapidly brought to the surface of platelets upon activation. By linking fibrinogen and modulating calcium signaling, but also by displaying anti-inflammatory properties, TLT-1 appears to play an important role in maintaining vascular homeostasis, regulating both adhesion, aggregation and inflammation at sites of injury/infection. Recent evidences highlight that a better understanding of TLT-1 signaling and regulation, but also the capacity to modulate its activity, will certainly open new realistic therapeutic perspectives.

Keywords : TLT-1, platelet aggregation, inflammation

 

About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]